Hughes R D, Langley P G, Guarner F, Williams R
J Pharm Pharmacol. 1986 Jan;38(1):63-5. doi: 10.1111/j.2042-7158.1986.tb04470.x.
The effect of 9 beta-methylcarbacyclin, a stable analogue of prostacyclin, as a platelet protective agent, has been investigated during in-vitro charcoal haemoperfusion with fresh heparinized human blood, a model of progressive platelet damage. There were no platelet losses over 3 h perfusion after an initial bolus (1 microgram ml-1) of 9 beta-methylcarbacyclin (101.6 +/- s.e. 1.9% of initial value) whereas in the paired control circuit there was a significant reduction in the platelet level (73.5 +/- 4.1%, P less than 0.05). Prevention of rises in plasma thromboxane B2 by 9 beta-methylcarbacyclin confirmed the lack of platelet damage and a significant, but less marked, effect on white cell losses was observed. In a second series of experiments a bolus of 9 beta-methylcarbacyclin in one circuit was compared with prostacyclin infusion in the other which demonstrated that this prostaglandin analogue was as effective as prostacyclin and on the basis of these initial results it would merit clinical evaluation.
在新鲜肝素化人血体外活性炭血液灌流（一种进行性血小板损伤模型）过程中，研究了前列环素的稳定类似物9β-甲基前列环素作为血小板保护剂的作用。在初始推注（1微克/毫升）9β-甲基前列环素后，3小时灌注期间无血小板损失（为初始值的101.6±标准误1.9%），而在配对的对照回路中，血小板水平显著降低（73.5±4.1%，P<0.05）。9β-甲基前列环素防止血浆血栓素B2升高证实无血小板损伤，并且观察到对白细胞损失有显著但不太明显的影响。在第二系列实验中，将一个回路中推注9β-甲基前列环素与另一个回路中输注前列环素进行比较，结果表明这种前列腺素类似物与前列环素一样有效，基于这些初步结果，它值得进行临床评估。
